CLIMB BIO, INC. Earnings Per Share, Basic and Diluted
CLIMB BIO, INC. (CLYM) reported Earnings Per Share, Basic and Diluted of -$0.50 per share for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-16.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-05-16
- CLIMB BIO, INC. earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$0.50.
- CLIMB BIO, INC. earnings per share, basic and diluted for the quarter ending 2021-12-31 was -$0.40.
- CLIMB BIO, INC. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.70.
- CLIMB BIO, INC. earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$3.11.
- CLIMB BIO, INC. earnings per share, basic and diluted for fiscal 2021 was -$4.24.
- CLIMB BIO, INC. earnings per share, basic and diluted for fiscal 2020 was -$10.49.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-03-31 | -$0.50 10-Q · filed 2022-05-16 | -$0.90 derived: net income ÷ weighted average shares · filed 2023-03-06 | -$1.53 derived: net income ÷ weighted average shares · filed 2023-03-06 | -$2.54 derived: net income ÷ weighted average shares · filed 2023-03-06 |
| 2021-12-31 | -$0.40 derived: net income ÷ weighted average shares · filed 2023-03-06 | -$1.02 derived: net income ÷ weighted average shares · filed 2023-03-06 | -$2.13 derived: net income ÷ weighted average shares · filed 2023-03-06 | -$4.24 10-K · filed 2022-03-07 |
| 2021-09-30 | -$0.70 10-Q · filed 2021-11-08 | -$2.29 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$5.49 10-Q · filed 2021-11-08 | -$8.91 derived: net income ÷ weighted average shares · filed 2022-11-14 |
| 2021-06-30 | -$3.11 10-Q · filed 2021-09-13 | -$8.80 10-Q · filed 2021-09-13 | -$13.74 derived: net income ÷ weighted average shares · filed 2022-08-15 | -$16.38 derived: net income ÷ weighted average shares · filed 2022-08-15 |
| 2021-03-31 | -$5.70 10-Q · filed 2022-05-16 | -$10.71 derived: net income ÷ weighted average shares · filed 2022-05-16 | -$13.50 derived: net income ÷ weighted average shares · filed 2022-05-16 | -$15.57 derived: net income ÷ weighted average shares · filed 2022-05-16 |
| 2020-12-31 | -$4.98 derived: net income ÷ weighted average shares · filed 2022-03-07 | -$7.35 derived: net income ÷ weighted average shares · filed 2022-03-07 | -$8.96 derived: net income ÷ weighted average shares · filed 2022-03-07 | -$10.49 10-K · filed 2022-03-07 |
| 2020-09-30 | -$1.46 10-Q · filed 2021-11-08 | -$2.58 derived: net income ÷ weighted average shares · filed 2021-11-08 | -$3.85 10-Q · filed 2021-11-08 | |
| 2020-06-30 | -$1.12 10-Q · filed 2021-09-13 | -$2.39 10-Q · filed 2021-09-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |